FDA
-
-
-
-
-
-
-
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
-
-
-
-
-
-
-
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Foll
-
-
-
-
-
-
-
Neurocrine presents tardive dyskinesia treatment data at conference
-
-
-
-
-
-
-
Bernstein SocGen Group Starts Neurocrine Bio. (NBIX) at Outperform
-
-
-
-
-
-
-
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
-
-
-
-
-
-
-
Neurocrine publishes tardive dyskinesia scale validation research
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $215 at H.C. Wainwright
-
328,285 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

